Matinas Biopharma Holdings Inc
5.0 %
199.01 %
Yet to be announced
Company Overview
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics using its lipid nanocrystal (LNC) platform delivery technology. The company's primary focus is on developing treatments for serious infections and other diseases with significant unmet medical needs.
The company's lead product candidate is MAT2203, an oral formulation of amphotericin B developed using the LNC platform technology, which is being developed for the treatment of serious fungal infections. Additionally, they are developing MAT2501, an oral formulation of amikacin for acute bacterial infections.
Revenue Sources
PassMatinas BioPharma is a pre-revenue company focused on developing medical treatments. The company is still in the research and development phase and has not generated any revenue in the past four quarters. Their business model and product pipeline are focused on developing legitimate medical treatments, which is halal.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company is pre-revenue and still in R&D phase. For the last four quarters, there has been no interest income or interest expense reported. Since the company is pre-revenue and in development stage, we skip the interest ratio calculations as they would not reflect the company's mature business model.
Operational Ethics
PassBased on review of company disclosures and public information, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, with no identified R&D centers or significant business relationships in Israel or direct ties to the Chinese Communist Party.
Comments